Addendum
Niraparib/abiraterone acetate (prostate cancer) – Addendum to Project A26-31
Report documents
-
Addendum
Niraparib/abiraterone acetate (prostate cancer) – Addendum to Project A26-31
Dossier assessment
Indication:
Adults with metastatic hormone-sensitive prostate cancer (mHSPC) and breast cancer-associated gene (BRCA)1/2 mutations (germline and/or somatic)
Result of dossier assessment:
- Patients with newly diagnosed high-risk mHSPC and BRCA1/2 mutations (germline and/or somatic): unchanged after addendum: added benefit not proven
- All other patients in the therapeutic indication: unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
03-09-2026 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A26-98
- Commission
- Commission awarded on 28.07.2026 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A26-98
Connected Projects
-
Dossier assessment
Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed